[Clinical studies on cefmenoxime in pediatric field]

Area of Science:

• Infectious Diseases
• Pharmacology
• Pediatrics

Background:

• Pediatric infections necessitate effective and safe antimicrobial agents.
• Cephalosporins are a critical class of antibiotics used in treating bacterial infections.
• Evaluating new antibiotics like cefmenoxime (CMX) is essential for expanding treatment options.

Observation:

• This study assessed the clinical effectiveness of cefmenoxime (CMX) in 22 pediatric patients (5 days to 8 years) with moderate to severe infections.
• Patients presented with diverse infections including bronchitis, pneumonia, sepsis, meningitis, and urinary tract infections.
• Cefmenoxime was administered intravenously, 4 times daily, at doses ranging from 40 to 200 mg/kg/day for approximately 3 to 15 days.

Findings:

• Cefmenoxime showed clinical effectiveness in all evaluable cases, with excellent, good, or fair responses in 17 out of 22 patients.
• Bacterial eradication was achieved for all 6 isolated causative bacterial strains, including S. pneumoniae, H. influenzae, E. coli, and K. pneumoniae.
• No notable adverse side effects were reported during the treatment period, indicating a favorable safety profile.

Implications:

• Cefmenoxime (CMX) presents a promising therapeutic option for managing serious pediatric bacterial infections.
• The antibiotic's efficacy and safety profile warrant further investigation in larger pediatric populations.
• This study contributes to the evidence base for using novel cephalosporins in pediatric infectious disease management.